NCT03632824

Tranexamic Acid in Pregnancies With Vaginal Bleeding

Tranexamic Acid for Antepartum Bleeding of Unknown Origin in the Second and Third Trimester: Nonrandomized Controlled Trials

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 139 (estimated)
• Sponsor: Hawler Medical University · Academic / Other
• Sex: Female
• Age: 18 Years – 42 Years
• Healthy volunteers: Not accepted

Summary

Tranexamic acid has been proposed and used for prevention and management of antepartum and postpartum hemorrhage.

Detailed description

Bleeding during pregnancy is associated with a three- to fourfold increase in perinatal mortality. Hemorrhage in pregnancy is characterized by activation of the fibrinolytic system. Tranexamic acid is a potent pharmaceutical agent that suppresses fibrinolysis, and thus can be used for managing hemorrhage in pregnancy. The FDA's pregnancy category for tranexamic acid is category B. Tranexamic acid has been used to decrease blood loss and treatment of intra partum blood loss in cesarean section also it has been used for prevention and management of postpartum hemorrhage after vaginal bleeding, regardless of whether the bleeding is due to genital tract trauma or other causes.

Conditions

• Vaginal Bleeding During Pregnancy

Interventions

Type	Name	Description
DRUG	Tranexamic Acid	One gram( 2 ampules ) of tranexamic acid was received by the participant intravenously twice daily for 48 hours followed by 500 mg tranexamic acid tablet three times daily for 5 days . follow up of the patient was done by recurrence of the bleeding latter on during pregnancy . the course of treatment was repeated again .

Timeline

• Start date: 2016-02-01
• Primary completion: 2020-01-15
• Completion: 2020-01-18
• First posted: 2018-08-15
• Last updated: 2020-01-22

Locations

1 site across 1 country: Iraq